OpenAI Invests in Merge Labs Noninvasive Brain-Chip Technology
OpenAI has invested $250 million in Merge Labs, a startup developing a brain-computer interface (BCI) that would be a rival to Elon Musk's Neuralink. The most distinguishing aspect of Merge Labs technology is its non-invasive method of implantation, where the skull of the patient is not opened.
A Non-Invasive Approach with Ultrasound
Unlike surgical BCI methods, Merge Labs' technology is based on a wireless and non-invasive approach. The company will now use ultrasound, which can establish the connection to brain activity in a person. This allows for applications in rehabilitation and other assistive devices for paralyzed individuals without surgery on their brain.
"Brain-computer interfaces (BCIs) are a significant new frontier. They open up new ways of communicating, learning, and interacting with technology. BCIs will create a natural, human-centered way to seamlessly interact with AI."
- From OpenAI Blog
Applications and Future Vision
In the future, Merge Labs' technology will apply to medical patients as well as healthy individuals. Theoretically, by implanting a brain-neural network interface, humans could control artificial intelligence applications only with their thoughts. No commercialization date for the interface has been released yet.
Investments and Valuations Facts
Merge Labs burst onto the public scene in August 2025. It now announces a $250 million seed funding round closed with OpenAI leading. This renders the startup's valuation to be around $850 million. Other participants of this round include Interface Fund, Bain Capital, Fifty Years, and Valve CEO Gabe Newell.
